Published in Nat Clin Pract Oncol on July 01, 2008
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res (2008) 8.12
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet (2012) 7.31
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist (2009) 6.00
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
A Randomized, Controlled Trial of Cavity Shave Margins in Breast Cancer. N Engl J Med (2015) 4.07
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet (2011) 3.60
Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med (2012) 3.38
Concern The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist (2003) 3.36
Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2013) 3.35
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol (2012) 2.98
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol (2007) 2.90
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A (2010) 2.79
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 2.75
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol (2005) 2.69
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res (2009) 2.49
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res (2010) 2.26
Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat (2003) 2.26
Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol (2007) 2.19
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. J Natl Cancer Inst (2010) 2.16
Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A (2005) 2.16
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J (2003) 2.11
Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist (2008) 2.10
Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer (2003) 2.01
The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform (2009) 1.98
Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol (2009) 1.93
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat (2011) 1.90
Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol (2011) 1.86
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res (2010) 1.81
Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J Clin Oncol (2011) 1.79
Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics (2004) 1.76
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2010) 1.70
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol (2010) 1.63
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer (2011) 1.53
Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol (2011) 1.52
Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res (2007) 1.52
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat (2007) 1.47
Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2010) 1.44
Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer. Ann Surg Oncol (2011) 1.44
Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res (2009) 1.43
Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst (2011) 1.38
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. Cancer (2010) 1.34
Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. J Clin Oncol (2008) 1.33
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics (2011) 1.32
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer (2004) 1.30
Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. Clin Cancer Res (2007) 1.28
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat (2012) 1.26
Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol (2011) 1.26
Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat (2009) 1.25
Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat Clin Pract Oncol (2006) 1.24
Targeted therapies for cancer 2004. Am J Clin Pathol (2004) 1.23
Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer (2004) 1.22
Primary systemic chemotherapy of invasive lobular carcinoma of the breast. Lancet Oncol (2007) 1.20
Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat (2005) 1.20
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat (2010) 1.19
Research issues affecting preoperative systemic therapy for operable breast cancer. J Clin Oncol (2008) 1.18
Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer. Oncologist (2012) 1.18
Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer (2010) 1.18
Unvalidated antibodies and misleading results. Breast Cancer Res Treat (2014) 1.17
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer (2011) 1.16
Multigene prognostic tests in breast cancer: past, present, future. Breast Cancer Res (2015) 1.16
Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res (2008) 1.15
Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer. Proc Natl Acad Sci U S A (2012) 1.14
The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res (2005) 1.12
Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn (2003) 1.12
Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J Mol Diagn (2005) 1.11
Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol (2010) 1.09
The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. Drug Resist Updat (2010) 1.08
Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J (2002) 1.07
CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist (2009) 1.05
Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Res Treat (2011) 1.05
DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist (2013) 1.04
Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer (2012) 1.04
Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg (2006) 1.03
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS One (2011) 1.03
PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer. Breast Cancer Res (2008) 1.02
Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer. Clin Cancer Res (2003) 1.02
Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer. Clin Cancer Res (2013) 1.01
Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res (2012) 1.00
Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel. Cancer (2010) 0.99
Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist (2010) 0.97
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer. J Clin Oncol (2003) 0.97
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer (2007) 0.97
High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat (2012) 0.97